148 related articles for article (PubMed ID: 37700392)
1. ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2.
Ma X; Fan M; Yang K; Wang Y; Hu R; Guan M; Hou Y; Ying J; Deng N; Li Q; Jiang G; Zhang Y; Zhang X
Cancer Sci; 2023 Nov; 114(11):4237-4251. PubMed ID: 37700392
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
3. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
5. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
6. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
7. KLF11 promotes the proliferation of breast cancer cells by inhibiting p53-MDM2 signaling.
Hou ZH; Tao M; Dong J; Qiu HM; Li F; Bai XY
Cell Signal; 2024 Aug; 120():111238. PubMed ID: 38810862
[TBL] [Abstract][Full Text] [Related]
8. SHARPIN Facilitates p53 Degradation in Breast Cancer Cells.
Yang H; Yu S; Wang W; Li X; Hou Y; Liu Z; Shi Y; Mu K; Niu G; Xu J; Wang H; Zhu J; Zhuang T
Neoplasia; 2017 Feb; 19(2):84-92. PubMed ID: 28063307
[TBL] [Abstract][Full Text] [Related]
9. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
10. Functional role of RRS1 in breast cancer cell proliferation.
Song J; Ma Z; Hua Y; Xu J; Li N; Ju C; Hou L
J Cell Mol Med; 2018 Dec; 22(12):6304-6313. PubMed ID: 30320499
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
12. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
13. Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation.
Li C; Lee H; Jung JH; Zhang Y; Wang J; Liu C; Sheffmaker RL; Segall AM; Zeng SX; Lu H
Oncogene; 2023 Jan; 42(2):154-164. PubMed ID: 36396725
[TBL] [Abstract][Full Text] [Related]
14. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
16. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
17. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
18. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2.
Jansson MD; Damas ND; Lees M; Jacobsen A; Lund AH
Oncogene; 2015 Apr; 34(15):1908-18. PubMed ID: 24882579
[TBL] [Abstract][Full Text] [Related]
19. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
20. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
